Demographics of the severe asthma and mild to moderate asthma cohorts
| Severe asthma, N=51 | Mild–moderate asthma, N=28 | p | |
| Age (years), mean (±SD) | 12.95 (2.7) | 11.06 (2.2) | 0.003 |
| Sex, M/F | 25/26 | 13/15 | 0.825 |
| Baseline FEV1 (%), predicted mean (±SD) | 79.4 (13.8) | 76.9 (16.3) | 0.473 |
| Atopic, n (%) | 43 (84) | 22 (79) | 0.523 |
| Dose of ICS, FP equivalent (μg/day), median (IQR) | 500 (500–1000) | 200 (100–344) | <0.001 |
| Subjects prescribed ICS, n (%) | 51 (100%) | 23 (82%) | 0.002 |
| Subjects prescribed maintenance OCS, n (%) | 8 (16%) | 0 | 0.027 |
| Subjects prescribed LABA, n (%) | 51 (100%) | 18 (64%) | <0.001 |
| Subjects prescribed LRTA, n (%) | 20 (39%) | 3 (11%) | 0.008 |
Figures in italics: p value is statistically significant (<0.05).
FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β agonist; LRTA, leukotriene receptor antagonist; OCS, oral corticosteroid.